FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3178584918> ?p ?o ?g. }

• W3178584918 endingPage "79.e3" @default.
• W3178584918 startingPage "72" @default.
• W3178584918 abstract "Background and Aims The effectiveness of vonoprazan relative to that of proton pump inhibitors (PPIs) after gastric endoscopic submucosal dissection (ESD) is unclear. Although previous studies used post-ESD ulcer healing as the outcome measure, post-ESD bleeding rate is the most objective and appropriate outcome measure because it has less ascertainment bias. We aimed to compare the post-ESD bleeding rates between vonoprazan and PPIs. Methods This nationwide population-based retrospective cohort study was conducted between 2014 and 2018 and involved 9 hospitals. After 2 days of intravenous PPI administration, either vonoprazan or PPI was administrated from postoperative day 2 to 30. Results Overall, data of 1715 patients (627 patient pairs) were analyzed through propensity score matching. The vonoprazan group had significantly lower post-ESD bleeding rates than the PPI group (overall, 11.9% vs 17.2%, P = .008; bleeding between days 2 and 30, 7.8% vs 11.8%, P = .015). The readmission rate because of post-ESD bleeding was lower in the vonoprazan group (2.4% vs 4.1%, P = .081). Blood transfusion (2.1% vs 3.0%, P = .15) and additional surgery because of delayed perforation (.5% vs 1.0%, P = .32) were not significantly different between the 2 groups. No deaths within 30 days occurred in both groups. On Cox regression analysis, vonoprazan use, lesion location (antrum), aspirin use, direct oral anticoagulant use, and Charlson Comorbidity Index (≥2) were associated with an increased risk of post-ESD bleeding within 30 days. Conclusions Vonoprazan has a lower post-ESD bleeding rate than PPIs. Further prospective studies are required to confirm these results. The effectiveness of vonoprazan relative to that of proton pump inhibitors (PPIs) after gastric endoscopic submucosal dissection (ESD) is unclear. Although previous studies used post-ESD ulcer healing as the outcome measure, post-ESD bleeding rate is the most objective and appropriate outcome measure because it has less ascertainment bias. We aimed to compare the post-ESD bleeding rates between vonoprazan and PPIs. This nationwide population-based retrospective cohort study was conducted between 2014 and 2018 and involved 9 hospitals. After 2 days of intravenous PPI administration, either vonoprazan or PPI was administrated from postoperative day 2 to 30. Overall, data of 1715 patients (627 patient pairs) were analyzed through propensity score matching. The vonoprazan group had significantly lower post-ESD bleeding rates than the PPI group (overall, 11.9% vs 17.2%, P = .008; bleeding between days 2 and 30, 7.8% vs 11.8%, P = .015). The readmission rate because of post-ESD bleeding was lower in the vonoprazan group (2.4% vs 4.1%, P = .081). Blood transfusion (2.1% vs 3.0%, P = .15) and additional surgery because of delayed perforation (.5% vs 1.0%, P = .32) were not significantly different between the 2 groups. No deaths within 30 days occurred in both groups. On Cox regression analysis, vonoprazan use, lesion location (antrum), aspirin use, direct oral anticoagulant use, and Charlson Comorbidity Index (≥2) were associated with an increased risk of post-ESD bleeding within 30 days. Vonoprazan has a lower post-ESD bleeding rate than PPIs. Further prospective studies are required to confirm these results." @default.
• W3178584918 created "2021-07-19" @default.
• W3178584918 creator A5002608528 @default.
• W3178584918 creator A5004555604 @default.
• W3178584918 creator A5006496018 @default.
• W3178584918 creator A5012622169 @default.
• W3178584918 creator A5041221171 @default.
• W3178584918 creator A5042725263 @default.
• W3178584918 creator A5048087220 @default.
• W3178584918 creator A5059872341 @default.
• W3178584918 creator A5059914715 @default.
• W3178584918 creator A5067776411 @default.
• W3178584918 creator A5076160893 @default.
• W3178584918 creator A5080943867 @default.
• W3178584918 creator A5086205215 @default.
• W3178584918 date "2022-01-01" @default.
• W3178584918 modified "2023-09-30" @default.
• W3178584918 title "Vonoprazan versus proton pump inhibitors for postendoscopic submucosal dissection bleeding in the stomach: a multicenter population-based comparative study" @default.
• W3178584918 cites W1577087691 @default.
• W3178584918 cites W1846268769 @default.
• W3178584918 cites W1929068538 @default.
• W3178584918 cites W1987427642 @default.
• W3178584918 cites W2000445173 @default.
• W3178584918 cites W2069745112 @default.
• W3178584918 cites W2072080364 @default.
• W3178584918 cites W2153747407 @default.
• W3178584918 cites W2492840086 @default.
• W3178584918 cites W2516103798 @default.
• W3178584918 cites W2555206525 @default.
• W3178584918 cites W2591332913 @default.
• W3178584918 cites W2592987351 @default.
• W3178584918 cites W2774222399 @default.
• W3178584918 cites W2782592164 @default.
• W3178584918 cites W2793965036 @default.
• W3178584918 cites W2794240184 @default.
• W3178584918 cites W2810584369 @default.
• W3178584918 cites W2819750453 @default.
• W3178584918 cites W2889276814 @default.
• W3178584918 cites W2891208097 @default.
• W3178584918 cites W2952756922 @default.
• W3178584918 cites W2960819354 @default.
• W3178584918 cites W2977571361 @default.
• W3178584918 cites W3013787143 @default.
• W3178584918 cites W3113000288 @default.
• W3178584918 cites W4236081165 @default.
• W3178584918 doi "https://doi.org/10.1016/j.gie.2021.06.032" @default.
• W3178584918 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34237329" @default.
• W3178584918 hasPublicationYear "2022" @default.
• W3178584918 type Work @default.
• W3178584918 sameAs 3178584918 @default.
• W3178584918 citedByCount "8" @default.
• W3178584918 countsByYear W31785849182021 @default.
• W3178584918 countsByYear W31785849182022 @default.
• W3178584918 countsByYear W31785849182023 @default.
• W3178584918 crossrefType "journal-article" @default.
• W3178584918 hasAuthorship W3178584918A5002608528 @default.
• W3178584918 hasAuthorship W3178584918A5004555604 @default.
• W3178584918 hasAuthorship W3178584918A5006496018 @default.
• W3178584918 hasAuthorship W3178584918A5012622169 @default.
• W3178584918 hasAuthorship W3178584918A5041221171 @default.
• W3178584918 hasAuthorship W3178584918A5042725263 @default.
• W3178584918 hasAuthorship W3178584918A5048087220 @default.
• W3178584918 hasAuthorship W3178584918A5059872341 @default.
• W3178584918 hasAuthorship W3178584918A5059914715 @default.
• W3178584918 hasAuthorship W3178584918A5067776411 @default.
• W3178584918 hasAuthorship W3178584918A5076160893 @default.
• W3178584918 hasAuthorship W3178584918A5080943867 @default.
• W3178584918 hasAuthorship W3178584918A5086205215 @default.
• W3178584918 hasConcept C126322002 @default.
• W3178584918 hasConcept C141071460 @default.
• W3178584918 hasConcept C167135981 @default.
• W3178584918 hasConcept C17923572 @default.
• W3178584918 hasConcept C191897082 @default.
• W3178584918 hasConcept C192562407 @default.
• W3178584918 hasConcept C2777137803 @default.
• W3178584918 hasConcept C2777628954 @default.
• W3178584918 hasConcept C2778456384 @default.
• W3178584918 hasConcept C2778527123 @default.
• W3178584918 hasConcept C71924100 @default.
• W3178584918 hasConcept C90924648 @default.
• W3178584918 hasConceptScore W3178584918C126322002 @default.
• W3178584918 hasConceptScore W3178584918C141071460 @default.
• W3178584918 hasConceptScore W3178584918C167135981 @default.
• W3178584918 hasConceptScore W3178584918C17923572 @default.
• W3178584918 hasConceptScore W3178584918C191897082 @default.
• W3178584918 hasConceptScore W3178584918C192562407 @default.
• W3178584918 hasConceptScore W3178584918C2777137803 @default.
• W3178584918 hasConceptScore W3178584918C2777628954 @default.
• W3178584918 hasConceptScore W3178584918C2778456384 @default.
• W3178584918 hasConceptScore W3178584918C2778527123 @default.
• W3178584918 hasConceptScore W3178584918C71924100 @default.
• W3178584918 hasConceptScore W3178584918C90924648 @default.
• W3178584918 hasIssue "1" @default.
• W3178584918 hasLocation W31785849181 @default.
• W3178584918 hasLocation W31785849182 @default.
• W3178584918 hasOpenAccess W3178584918 @default.
• W3178584918 hasPrimaryLocation W31785849181 @default.
• W3178584918 hasRelatedWork W2332797319 @default.

• next